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Abstract
Background: The transient receptor potential, subfamily V, member 6 (TRPV6) is a Ca2+ selective
cation channel. Several studies have shown that TRPV6 transcripts are expressed in locally
advanced prostatic adenocarcinoma, metastatic and androgen-insensitive prostatic lesions but are
undetectable in healthy prostate tissue and benign prostatic hyperplasia. Two allelic variants of the
human trpv6 gene have been identified which are transcribed into two independent mRNAs,
TRPV6a and TRPV6b. We now asked, whether the trpv6a allele is correlated with the onset of
prostate cancer, with the Gleason score and the tumour stage.
Methods: Genomic DNA of prostate cancer patients and control individuals was isolated from
resections of prostatic adenocarcinomas and salivary fluid respectively. Genotyping of SNPs of the
TRPV6 gene was performed by restriction length polymorphism or by sequencing analysis. RNA
used for RT-PCR was isolated from prostate tissue. Data sets were analyzed by Chi-Square test.
Results: We first characterized in detail the five polymorphisms present in the protein coding
exons of the trpv6 gene and show that these polymorphisms are coupled and are underlying the
TRPV6a and the TRPV6b variants. Next we analysed the frequencies of the two TRPV6 alleles using
genomic DNA from saliva samples of 169 healthy individuals. The homozygous TRPV6b genotype
predominated with 86%, whereas no homozygous TRPV6a carriers could be identified. The
International HapMap Project identified a similar frequency for an Utah based population whereas
in an African population the a-genotype prevailed. The incidence of prostate cancer is several times
higher in African populations than in non-African and we then investigated the TRPV6a/b
frequencies in 141 samples of prostatic adenocarcinoma. The TRPV6b allele was found in 87% of
the samples without correlation with Gleason score and tumour stage.
Conclusion: Our results show that the frequencies of trpv6 alleles in healthy control individuals
and prostate cancer patients are not significantly different. Although expression of trpv6 transcripts
correlates with aggressive potential of prostate cancer, the TRPV6 genotype does not correlate
with the onset of prostate cancer, with the Gleason score and the tumour stage.
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Background
Intracellular calcium levels are highly regulated to achieve
precise regulation of cell signalling pathways. These path-
ways lead to muscle contraction, synaptic transmission,
hormone secretion as well as apoptosis and cell prolifera-
tion. The major protein classes involved in calcium home-
ostatsis are calcium pumps, sodium/calcium exchangers
and Ca2+ permeable cation channels. An upregulation of
IP3 receptor channels [1,2], voltage gated calcium chan-
nels [3-5] and TRP-channels has been demonstrated in
various cancer tissues including prostatic adenocarcinoma
tissue [6-8]. Among the TRP-calcium channel family
TRPM4 has been shown to be expressed in benign and
malign prostate tissue [9]whereas TRPM8 is overexpressed
in prostate cancer [6]. TRPM8 and TRPM4 are non-selec-
tive cation channels and TRPM4 is not permeable for
Ca2+. In contrast TRPV6 is a highly Ca-selective cation
channel and its transcripts are overexpressed in prostatic
adenocarcinoma but undetectable in healthy and benign
prostate tissue [7,10]. In prostate tissue the expression of
TRPV6 is strictly correlated with the Gleason grading and
the tumour staging implying that TRPV6 is an indicator
for the metastatic potential of prostatic adenocarcinoma
and a potential target for drugs which may be used to treat
this disease [11]. Analysis of 40 tissue samples showed
that TRPV6 transcripts occur in more than 90% of patients
with extraprostatic prostatic adenocarcinoma indicating
that patients with TRPV6 positive tumours have a bad
prognosis [11]. Overexpression of TRPV6 stimulates pro-
liferation of HEK293 cells in a calcium dependent manner
[12].
Previously we isolated two allelic TRPV6 variants from
human placenta [7]. The cDNAs of these variants differ in
5 base pairs (bp). Two nucleotide substitutions, a1080g
and g1787a, are silent whereas three substitutions
resulted in changes of the encoded amino acid residues
R157 to C157 (R157C), V378 to M378 (V378M) and T681 to
M681  (T681M). The resulting protein sequences were
called TRPV6a (accession number: AJ243500) and
TRPV6b (AJ243501). We suggested that these 5 bp repre-
sent a coupled polymorphism [7].
Based on this study we now examined whether genotyp-
ing of one of the polymorphisms within the protein cod-
ing region of the TRPV6 cDNA is sufficient to predict
expression of the TRPV6a or TRPV6b variant. In addition,
we asked whether expressing of the TRPV6a or TRPV6b
variant, respectively, correlates with the occurrence of pro-
static adenocarcinoma, its onset and aggressiveness. We
determined the frequencies of the two TRPV6 alleles
within Caucasians and compared these frequencies with
genotypes obtained from prostatic adenocarcinoma spec-
imen. Apparently, the frequency of either TRPV6 variant is
not associated with the onset of prostate cancer and does
not correlate to the Gleason score and to the tumour stage.
Methods
All experiments were approved by the local state's ethical
committee (Ethik-Kommission of the Ärztekanmmer des
Saarlandes, Saarbrücken, Germany).
Genotyping of TRPV6 alleles
To analyze polymorphism 1 a genomic DNA fragment of
the TRPV6 gene was amplified (primer pair 430/431; see
Figure 1 and Table 1) and restricted by FauI; the fragments
were separated by 5% polyacrylamide gels. The expected
sizes of the fragments were 283 and 465 bp (b/b geno-
type), 54, 229 and 465 bp (a/a genotype) and 54, 229,
283 and 465 bp (a/b genotype). To analyze polymor-
phism 2 a genomic DNA fragment of the TRPV6 gene was
amplified (primer pair 243/244; see Figure 1 and Table 1)
and restricted by Bsp1286I; the expected sizes of the frag-
ments were 57, 125 and 276 bp (b/b genotype), 125 and
333 bp (a/a genotype) and 57, 125, 276 and 333 bp (a/b
genotype). To analyze the fourth and fives polymorphism
we amplified a genomic fragment of the TRPV6 gene with
the primer pair 778/779 and sucloned the amplified DNA
in the plasmid pBluescript (Stratagen) and sequenced
more than 10 individual clones on both strands.
Isolation of genomic DNA and RNA
Genomic DNA was isolated from frozen prostate tissue
(~0.5 g) with the QIAamp DNA Mini Kit (Qiagen). Sali-
vary was obtained from healthy individuals of Caucasian
origin. Male individuals were without known prostate dis-
ease. Genomic DNA from control samples was isolated
from salivary using the QIAamp Blood Mini Kit (Qiagen)
with the following modifications: The salivary (1 ml) was
diluted in 4 ml PBS-buffer, and centrifuged 10 min at
3000 g. The cell sediment was resuspended in 180 μl PBS
and digested in the presence of 20 μl ProteinaseK (60 U/
ml) and 200 μl AL buffer (Qiagen) at 56°C for 10 min fol-
lowed by the addition of 200 μl ETOH (100%). The sam-
ple was applied to a Qiamp spin column and the genomic
DNA was isolated according to the manufacturer instruc-
tions. Total RNA was isolated from 0.5 g frozen prostate
tissue using the peqGold RNA Pure (Peqlab). First strand
was synthesized using the SuperScript First-Strand Synthe-
sis System for RT-PCR (Invitrogen). DNA-sequencing was
carried out with a capillary sequencer (ABI) using the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems). DNA fragments were subcloned in pBlue-
script and transformed in XL1 competent cells (Strata-
gene). Plasmids were isolated using a plasmid Midi Kit
(Qiagen). PCR reactions were typically run in a total vol-
ume of 50 μl using the phusion proof reading polymerase
(NEB). The annealing temperatures were adjusted to
58°C, elongation time depending on fragment length was
adjusted to 20 sec/1 kb.
Prostate tissue samples: Patients' informed consent was
obtained prior to all investigations. Only patients withBMC Cancer 2009, 9:380 http://www.biomedcentral.com/1471-2407/9/380
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Genotyping of TRPV6 alleles Figure 1
Genotyping of TRPV6 alleles. A, TRPV6 locus on human chromosome 7. Genes adjacent to TRPV6 are EPHB (ephrin 
receptor precursor), TRPV5 and KEL (Kell blood group antigen). Below the structure of the TRPV6 gene with the 15 exons 
and the coupled polymorphisms 1, 2, 3, 4, and 5. Polymorphisms within introns are not included. The polymorphisms 1, 3 and 
5, but not polymorphisms 2 and 4, affect the TRPV6 protein sequence. B, Genotyping of TRPV6 alleles by restriction of ampli-
fied DNA using FauI and Bsp1286I to analyze polymorphism 1 (left) and polymorphism 2 (middle) and direct sequencing of 
amplified DNA to analyze polymorphism 4 and 5 (right). Arrows indicate positions of primer pairs used for DNA amplification.BMC Cancer 2009, 9:380 http://www.biomedcentral.com/1471-2407/9/380
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primary prostatic acinar adenocarcinomas were included
in the study. Radical prostatectomy specimens were
placed on ice after removal and immediately transferred
to the Institute of Pathology. The native prostate was sub-
sequently processed according standard protocols [13].
Tumour-suspicious and tumour-free areas were resected
and snap frozen in liquid nitrogen and stored at -80°C
until use. The remaining material was fixed in 4% buff-
ered formaldehyde for 24 hours. The frozen sections of
the native material identified tumour and tumour-free
areas and were included in the diagnostic process. The
grading was performed in accordance to the 2005 modi-
fied Gleason score [14]. Low-grade tumours were defined
as tumours with Gleason scores 5 to 6, high grade
tumours as Gleason scores 7 to 10. The staging was per-
formed in accordance to the 6th edition of the UICC TNM
staging system of malignant tumours (2002). Saliva for
genotyping was obtained from 169 healthy volunteers.
Volunteers informed consent was obtained before all
investigations.
Allele frequencies were analyzed by Chi Square test.
Results
Coupled polymorphisms of the TRPV6 gene
The human TRPV6 gene is located on the chromosome
7q33-34 adjacent to the TRPV5 and EPHB6 genes and its
coding sequence encompasses 15 exons (Figure 1A, [15]).
Earlier we isolated TRPV6 cDNA clones from a human
placenta cDNA library and found two cDNAs comprising
5 single nucleotide polymorphisms (SNPs, [7]). These
polymorphisms are located in exons 4, 8, 9 14 and 15 and
were numbered from 1 to 5 (Figure 1). The polymor-
phisms on exon 8 (a/g) and on exon 14 (g/a) represent
silent base pair exchanges whereas changes of c to t (exon
4), g to a (exon 9) and c to t (exon 14) lead to the amino
acid substitutions Arg157Cys, Val378Met and Thr681Met
in the deduced protein sequence. From the data we con-
cluded that from the two alleles two TRPV6 proteins are
translated, one, TRPV6a, with the amino acids R157, V378
and T681 and a second variant, TRPV6b, with the amino
acid residues C157, M378 an M681.
The polymorphism on exon 4 can be analyzed by the
restriction enzyme FauI, because the sequence of the
TRPV6a allele contains an additional FauI restriction side
not present in the TRPV6b allele (Figure 1). A second
restriction fragment length polymorphism occurs on exon
8 with the restriction enzyme Bsp1286I. To study if the
polymorphisms are typically coupled we isolated
genomic DNA from salivary obtained from 36 healthy
volunteers and amplified DNA fragments using the
primer pair 430/431 that flank exons 3 and 4. The ampli-
fied DNA fragment covering exons 3 and 4 and the intron
sequence in between was restricted with FauI and the frag-
ment length polymorphisms analyzed by polyacrylamide
gels. The expected fragment sizes were 465, 229 and 54 bp
for TRPV6 alleles a/a, 465, 283, 229, and 54 bp for alleles
a/b and 465 and 283, for alleles b/b (Figure 1). Next we
analyzed the first polymorphism of the 36 individuals. 19
of the 36 samples were of the b/b genotype and 17 were
heterozygous (a/b); the a/a genotype was not detected. To
test if this first polymorphism is coupled to the second we
amplified the DNA encoding exon 8 and 9, including the
intron in between, with the primers 243/244 from the 36
individuals and cut the fragments by Bsp1286I. The 19
samples that exhibited the b/b genotype at the first poly-
morphic side were b/b genotyped at the second side and
as expected the remaining 17 individuals exhibited the
heterozygous genotype a/b supporting the conclusion
that the polymorphisms within the homozygous individ-
uals, and apparently in the heterozygous individuals are
coupled, as suggested previously [7].
TRPV6 is overexpressed in prostatic adenocarcinoma tis-
sue and we next extracted genomic DNA from a total of
142 prostate tissue samples and analyzed the second pol-
ymorphism by the restriction enzyme Bsp1286I. The DNA
of one out of the 142 tissue samples (sample 88, see Addi-
tional file 1) was of the a/a genotype at the second poly-
morphic side. We analyzed the first polymorphic side and
found the genotype a/a indicating that this sample con-
tains homozygous TRPV6a alleles (Figure 1). To test if the
fourth and fifth polymorphisms were coupled to the first
and second, we further amplified DNA fragments from
sample 88 containing exons 14 and 15 using the primer
pair 778/779. The amplified DNA fragments were sub-
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cloned and ten individual clones were sequenced. The
sequence of all a-alleles show that the polymorphisms are
coupled. Four prostate tissue samples exhibiting the b/b
genotype at the second polymorphic side were analyzed
in a similar way. The 4 DNAs were genotype b/b at the
first, fourth and fifth polymorphic side. Furthermore we
extracted total RNA from a pool of ten prostate cancer
patients and amplified the full length coding sequence of
the TRPV6 cDNA. The cDNAs of ten individual clones
were subcloned and sequenced. Nine clones reflect the
TRPV6b and one the a-allele also indicating a coupling of
the polymorphisms.
Allele frequencies of prostate cancer patients
The incidence of prostatic adenocarcinoma depends on
non genetic factors but also on ethnicity and familial
background [16]. We therefore asked if the TRPV6 geno-
type is correlated with prostatic adenocarcinoma and its
progression. We first determined the TRPV6 allele fre-
quencies of 169 healthy Caucasians by analyzing the sec-
ond polymorphic side in DNA obtained from salivary as
described above (Figure 1). We found that 145 (86%) of
healthy control individuals were of the homozygous
TRPV6 genotype b/b whereas the homozygous genotype
a/a was not detected. The allele frequencies of males and
females are not statistically different (males 65 (84%);
females 80 (87%) (Figure 2A). Data from the HapMap
project http://www.HapMap.org/ indicate that the fre-
quency of TRPV6a alleles in Africans is higher [17]. The
HapMap project sequenced the genomic locus of TRPV6
of 30 individuals from Yoruba/Nigeria and found a higher
frequency of a-alleles within this population (43% a/a,
42% a/b, 15% b/b). Similar TRPV6 allele frequencies in
Africans and black Americans were published recently
[18,19]. In addition prostatic adenocarcinomas occur
more often in the black population of the US [16].
This finding raised the question if a higher TRPV6a allele
frequency correlates with an increase of the incidence of
prostatic adenocarcinoma. Therefore we compared the
TRPV6 allele frequencies from Caucasian control individ-
uals with the DNA obtained from prostatic adenocarci-
noma tissue samples. We isolated genomic DNA from 142
prostatic adenocarcinoma resections and genotyped the
samples using the restriction enzyme Bsp1286I. 125
(88%) of the prostate tissue samples exhibit the genotype
b/b, 16 (11.3%) the heterozegous genotype and only one
sample was homozygous a/a (0.7%). These data show
that allele frequencies of healthy male individuals (84%
b/b) and prostate cancer patients (88% b/b) are very sim-
ilar (Figure 2B). Prostate cancer patients can be assigned
to two cohorts [20], one representing patients below 60
years of age (early onset of prostate cancer) and a second
with patients above 60 years (late onset of prostate can-
cer). Only from 99 of the 142 tissue samples the date
when prostatic adenocarcinoma was diagnosed was
known. After assigning the tissue samples to either cohort
we found allele frequencies of 94% (b/b) and 6% (a/b) in
the first and 87% (b/b), 12% (a/b) and 1% (a/a) in the
second. Because early onset of prostate cancer is relatively
rare only 17 tissue samples of 99 from the patients exam-
ined belong to this group. However, the allele frequencies
between these groups are similar (Figure 2C) indicating
that onset of prostate cancer is independent of the TRPV6
genotype.
Next, we assigned the prostatic adenocarcinoma tissue
samples to the Gleason score which describes the differen-
tiation of the prostate tissue and is indicative of the malig-
nancy of a tumour.
The Gleason score is written as the sum of the two most
prominent Gleason patterns. A Gleason score of >7 is cor-
related with a highly malignant tumour whereas a low
Gleason score (<7) is an indicator of weaker aggressive-
ness [21,22].
Similar TRPV6 allele frequencies were found if the pros-
tate tissue samples were grouped according to the Gleason
score, 83% of the low grade Gleason tumours exhibited
the homozygous b/b genotype, 89% b/b of the high grade
Gleason tumours (Figure 2D).
Prostate tumours of stage pT2 are confined to the prostate
whereas the tumours of the stages pT3a, pT3b and pT4 are
not restricted to the prostate and represent extraprostatic
tumours at the time of resection. The tumour stage pT1a/
b represents tumours that are found incidentally during
the resection of hyperplastic prostate tissue. More than
90% of pT3b tumours express TRPV6 transcripts, whereas
TRPV6 expression is only in 20% of pT2 tumours detecta-
ble [11]. The percentage of pT1a/b and pT2 tumours
which have the potency to develop biological aggressive
potential is unknown. It is commonly believed that the
fraction of clinical irrelevant tumours within the group of
pT1a/b and pT2 tumours is relatively high [23]. Therefore
we asked whether TRPV6 allele frequencies of extrapros-
tatic and intra-prostatic tumours (at time of resection) are
different or not. Comparing the allele frequencies of
patients with pT1a/b and pT2 tumours with patients with
extraprostatic tumours (pT3-pT4) we found no significant
difference between these two groups. 94% of the pT1a/b
and pT2 tumours were genotyped b/b and 87% of the
pT3-pT4 tumours (Figure 2E). The results indicate that the
TRPV6 genotype is not correlated with an extraprostatic
tumour growth. To demonstrate that TRPV6 is indeed
expressed in the tumour tissue that we used for genotyp-
ing we randomly tested TRPV6 expression by conven-
tional RT-PCR using tumour samples of patients 3, 19, 20,
27 and 87. In all samples TRPV6 specific amplicons wereBMC Cancer 2009, 9:380 http://www.biomedcentral.com/1471-2407/9/380
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TRPV6 allele frequencies in prostate cancer patients Figure 2
TRPV6 allele frequencies in prostate cancer patients. (A) Comparison of TRPV6 allele frequencies in salivary from Cau-
casian males and females, (n = 169, χ2 = 0.22, p > 0.1), (B) tissue samples from healthy males (n = 77) and prostate cancer 
patients (n = 141, χ2 = 0.23, p > 0.1), (C) tissue samples from early onset prostate cancer patients (age < 60) and late onset 
patients (age > 60) (n = 99, χ2 = 0.58, p > 0.1), (D) tissue samples from patients with low Gleason scores (<7) and high Gleason 
scores (>7) (n = 90, χ2 = 0.69, p > 0.1) and (E) tissue samples from patients with the tumour stages pT1-pT2 and patients with 
the tumour stages pT3-pT4 (n = 99, χ2 = 0.03, p > 0.1).BMC Cancer 2009, 9:380 http://www.biomedcentral.com/1471-2407/9/380
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obtained as well as TRPM4 and hypoxanthin phosphori-
bosyltransferase type 1 (HPRT1) transcripts which we
used as positive controls (data not shown).
Discussion
We show that the 5 polymorphisms of the TRPV6 cDNA
that define TRPV6a and TRPV6b alleles are typically cou-
pled. We used the second polymorphisms for genotyping
to determine the TRPV6 allele frequencies in healthy Cau-
casians. We can demonstrate that within the Caucasian
population TRPV6b alleles are more frequent than
TRPV6a. Because TRPV6 transcripts are present in
advanced prostatic adenocarcinoma samples we asked if
the TRPV6 genotype may influence the progression of
prostate cancer. We genotyped tissue samples from 142
prostate cancer patients and found a similar distribution
of TRPV6 alleles as in healthy Caucasians. We show that
the TRPV6 genotype is not correlated with the onset of
prostate cancer. The small number of probes reflects that
early onset of prostate cancer is a rare event. However the
data show a tendency that the frequency of TRPV6a alleles
in the patient group is lower than in controls. Further-
more the TRPV6 genotype is not correlated with the
Gleason score and the tumour stage of prostatic adenocar-
cinoma samples.
TRPV6 exhibits a highly unusual coupled polymorphism
within the human population: While the ancestral allele
TRPV6a (R157, V378 and T681) is common among African
populations, the derived allele TRPV6b (C157, M378 and
M681) is predominant in all other tested population
groups suggesting that this haplotype conferred a tempo-
rally or geographically selective advantage [19]. The rea-
son for this selection has remained elusive and no
obvious differences in ion channel properties have been
found [24]. In addition, the incidence of prostatic adeno-
carcinoma within African/Afro-American populations is
higher than in Caucasians [25-27]. Previously we have
shown that TRPV6 overexpression correlates with extrap-
rostatic prostatic adenocarcinoma [11] and we asked
whether the ancestral TRPV6a allele is associated with this
finding. Our findings do not support the assumption that
the TRPV6a allele is correlated with a higher incidence of
prostatic adenocarcinoma.
We found only one patient with the genotype a/a and we
cannot exclude at this stage that the homozygous TRPV6a
allele is associated with the higher prostatic adenocarci-
noma incidence found in African/Afro-American people.
We re-analyzed the polymorphism of the TRPV6 locus
which had been identified by the HapMap project. The
HapMap project sequenced the genomic TRPV6 locus of
four ethnic groups (Yoruba/Nigeria, Utah/USA-European
Polymorphism of TRPV6a and TRPV6b alleles Figure 3
Polymorphism of TRPV6a and TRPV6b alleles. The TRPV6 gene consists of 15 exons (black boxes). The five polymor-
phisms located within protein coding exons are shown on top, polymorphisms within introns are shown below. The polymor-
phisms within introns http://www.HapMap.org/ are found with similar frequencies as the polymorphisms found within exons 
(see text).
Table 2: TRPV6 allele frequencies of four ethnic groups 
compared with data from this study
TRPV6 genotype (in %) a/a a/b b/b
Yorube (Africa) 43 42 15
Utah (USA) 0 12 88
Tokyo (Japan) 0 5 95
Beijing (China) 0.3 12.7 87
Data taken from the International HapMap Project (http://
www.HapMap.org/; [17]. The International Hap Map Project 
Website).BMC Cancer 2009, 9:380 http://www.biomedcentral.com/1471-2407/9/380
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based, Tokio/Japan, Beijing/China). These data include
the second polymorphism that we analyzed by RFLP and
the resulting genotype frequencies are summarized in
Table 2. It is striking that depending on the distance to the
African continent the frequency of the homozygous
TRPV6 b/b genotype increases and it was postulated that
the TRPV6 locus may be a target to positive selection thus
leading to an enhanced b/b genotype frequency within
the Europeans, European based Americans and within
Asian populations [18,28].
The TRPV6 locus contains more than 50 polymorphisms
which can be found in the HapMap Project (http://
www.HapMap.org/, Figure 3). The HapMap data show
that the 5 exon derived polymorphisms that we describe
and which are occurring in exon coding sequences do
have a similar frequency as 16 intron based polymor-
phisms. In addition these 16 polymorphisms had a simi-
lar frequency in the four ethnic groups shown in Table 2
as the 5 polymorphisms found in exon coding sequences
described here. Within the most adjacent genes TRPV5,
KEL and EPHB6, we did not find polymorphisms with
similar frequencies. We speculate that selection pressure
leading to an increase of TRPV6b alleles in non-African
based populations is based on the TRPV6 locus itself but
not on the adjacent genes.
Conclusion
TRPV6 transcripts are expressed in patients with advanced
prostatic adenocarcinoma but are not detectable in
healthy and benign prostate tissue. [7]. Within Caucasians
two allelic variants, TRPV6a and TRPV6b, are typically
present whereas ~87% of this population exhibit the
homozygous TRPV6b genotype. In African based Ameri-
cans TRPV6a alleles are much more frequent. The pros-
tatic adenocarcinoma incidence within African Americans
is 2-3 times increased compared to Caucasians. Because
Caucasians typically exhibit the homozygous TRPV6b (b/
b) or the hetereozygous a/b genotype we asked if the
occurrence of the heterozygous genotype in Caucasians is
correlated with the Gleason score, the tumour stage or the
onset of prostate cancer. From the data we conclude that
the TRPV6 genotype does not correlate with the progres-
sion of prostatic adenocarcinoma.
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